Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81. https://doi.org/10.1016/S0140-6736(10)61350-5.

Article  CAS  PubMed  Google Scholar 

Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol. 2005;46(7):1225–8.

Article  PubMed  Google Scholar 

Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, et al. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2021;28(11):1279–89. https://doi.org/10.1093/eurjpc/zwaa047.

Article  PubMed  Google Scholar 

Barter PJ, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein. A novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23:160–7.

Vasan RS, Pencina MJ, Robins SJ, Zachariah JP, Kaur G, D’Agostino RB, et al. Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Circulation. 2009;120(24):2414–20. https://doi.org/10.1161/CIRCULATIONAHA.109.872705.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brown ML, Inazu A, Hesler CB, Agellon LB, Mann C, Whitlock ME, et al. Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature. 1989;342(6248):448–51.

Article  CAS  PubMed  Google Scholar 

Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med. 1990;323(18):1234–8.

Article  CAS  PubMed  Google Scholar 

Ritsch A, Scharnagl H, Eller P, Tancevski I, Duwensee K, Demetz E, et al. Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Circulation. 2010;121(3):366–74. https://doi.org/10.1161/CIRCULATIONAHA.109.875013.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thompson A, Di Angelantonio E, Sarwar N, Erqou S, Saleheen D, Dullaart RP, et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA. 2008;299(23):2777–88.

Article  CAS  PubMed  Google Scholar 

Johannsen TH, Frikke-Schmidt R, Schou J, Nordestgaard BG, Tybjaerg-Hansen A. Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects. J Am Coll Cardiol. 2012;60(20):2041–8. https://doi.org/10.1016/j.jacc.2012.07.045.

Article  CAS  PubMed  Google Scholar 

Rittershaus CW, Miller DP, Thomas LJ, Picard MD, Honan CM, Emmett CD, et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol. 2000;20(9):2106–12.

Article  CAS  PubMed  Google Scholar 

Sugano M, Makino N, Sawada S, Otsuka S, Watanabe M, Okamoto H, et al. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem. 1998;273(9):5033–6.

Article  CAS  PubMed  Google Scholar 

Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 2000;406(6792):203–7.

Article  CAS  PubMed  Google Scholar 

Morehouse LA, Sugarman ED, Bourassa PA, Sand TM, Zimetti F, Gao F, et al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J Lipid Res. 2007;48(6):1263–72. https://doi.org/10.1194/jlr.M600332-JLR200.

Article  CAS  PubMed  Google Scholar 

Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350(15):1505–15.

Article  CAS  PubMed  Google Scholar 

Nicholls SJ, Ray KK, Ballantyne CM, Beacham LA, Miller DL, Ruotolo G, et al. Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: the ACCENTUATE trial. Atherosclerosis. 2017;261:12–8. https://doi.org/10.1016/j.atherosclerosis.2017.04.008.

Article  CAS  PubMed  Google Scholar 

Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109–22.

Article  CAS  PubMed  Google Scholar 

Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356(13):1304–16.

Article  CAS  PubMed  Google Scholar 

Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet. 2007;370(9582):153–60.

Article  CAS  PubMed  Google Scholar 

Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007;356(16):1620–30.

Article  CAS  PubMed  Google Scholar 

Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol. 2007;27(2):257–60.

Article  CAS  PubMed  Google Scholar 

Barter P. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Am J Cardiol. 2009;104(10 Suppl):10E-E15. https://doi.org/10.1016/j.amjcard.2009.09.014.

Article  CAS  PubMed  Google Scholar 

Vergeer M, Stroes ES. The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors. Am J Cardiol. 2009;104(10 Suppl):32E-E38. https://doi.org/10.1016/j.amjcard.2009.09.017.

Article  CAS  PubMed  Google Scholar 

Nicholls SJ, Tuzcu EM, Brennan DM, Tardif JC, Nissen SE. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation. 2008;118(24):2506–14.

Article  CAS  PubMed  Google Scholar 

Ray KK, Ditmarsch M, Kallend D, Niesor EJ, Suchankova G, Upmanyu R, et al. The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial. Eur Heart J. 2014;35(27):1792–800. https://doi.org/10.1093/eurheartj/ehu105.

Article  CAS  PubMed  Google Scholar 

Luscher TF, Taddei S, Kaski JC, Jukema JW, Kallend D, Munzel T, et al. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J. 2012;33(7):857–65. https://doi.org/10.1093/eurheartj/ehs019.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet. 2011;378(9802):1547–59. https://doi.org/10.1016/S0140-6736(11)61383-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089–99. https://doi.org/10.1056/NEJMoa1206797.

Article  CAS  PubMed  Google Scholar 

Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, Shao M, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA. 2011;306(19):2099–109. https://doi.org/10.1001/jama.2011.1649.

Article  CAS  PubMed  Google Scholar 

Nicholls SJ, Ruotolo G, Brewer HB, Kane JP, Wang MD, Krueger KA, et al. Cholesterol efflux capacity and pre-beta-1 HDL concentrations are increased in dyslipidemic patients treated with evacetrapib. J Am Coll Cardiol. 2015;66(20):2201–10. https://doi.org/10.1016/j.jacc.2015.09.013.

Article  CAS  PubMed  Google Scholar 

Nicholls SJ, Lincoff AM, Barter PJ, Brewer HB, Fox KA, Gibson CM, et al. Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: rationale and design of the ACCELERATE trial. Am Heart J. 2015;170(6):1061–9. https://doi.org/10.1016/j.ahj.2015.09.007.

Article  CAS  PubMed  Google Scholar 

Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380(9841):572–80. https://doi.org/10.1016/S0140-6736(12)60312-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363(25):2406–15. https://doi.org/10.1056/NEJMoa1009744.

Article  CAS  PubMed  Google Scholar 

Kastelein JJ, Besseling J, Shah S, Bergeron J, Langslet G, Hovingh GK, et al. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet. 2015;385(9983):2153–61.